1
|
Ran L, Li F, Jiang L, Yang L, Liu Y. Arterial perfusion chemoembolization combined with iodine-125 seeds for stage IIB osteosarcoma: A case report. Oncol Lett 2025; 30:347. [PMID: 40438873 PMCID: PMC12117397 DOI: 10.3892/ol.2025.15093] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2025] [Accepted: 05/01/2025] [Indexed: 06/01/2025] Open
Abstract
Osteosarcoma is a highly malignant bone tumor that predominantly affects adolescents. Its aggressive nature, complex treatment options and poor prognosis render it a notable concern in oncology. With advancements in therapy for osteosarcoma, neoadjuvant chemotherapy in conjunction with limb-salvage surgery has emerged as the preferred surgical strategy. However, the physical and emotional trauma associated with surgery, along with the adverse side effects of chemotherapy, can be unacceptable to some patients. In recent years, alternative local treatment modalities such as transarterial chemoembolization (TACE) and iodine-125 seed implantation have garnered considerable attention. These techniques show potential in enhancing local tumor control while minimizing systemic toxicity. TACE involves obstructing the blood supply to the tumor while administering localized chemotherapy, resulting in tumor ischemia and necrosis, which is particularly effective for hypervascular tumors. Meanwhile, iodine-125 seeds act as low-energy radiation sources that can effectively target tumor cells while sparing the surrounding healthy tissue. The present study describes a case of osteosarcoma treated with a combination of TACE and iodine-125 seed implantation. The patient, diagnosed with osteosarcoma of the left knee joint, declined surgical intervention. Consequently, a treatment plan involving TACE paired with iodine-125 seed implantation was established. Post-treatment follow-up demonstrated marked pain relief, improved limb function and a notable reduction in tumor volume with decreased bone destruction visible on imaging. Over a follow-up period of 6 years, there were no signs of disease recurrence or distant metastasis, and no notable chemotherapy-related side effects were reported. The quality of life of the patient was markedly improved. The current case illustrates the antitumor efficacy and reduced toxicity of combining TACE with iodine-125 seed implantation in the management of osteosarcoma.
Collapse
Affiliation(s)
- Linhao Ran
- Department of Nuclear Medicine, Banan Hospital of Chongqing Medical University, Chongqing 401320, P.R. China
| | - Fan Li
- Department of Ultrasound, Banan Hospital of Chongqing Medical University, Chongqing 401320, P.R. China
| | - Li Jiang
- Department of Ultrasound, Banan Hospital of Chongqing Medical University, Chongqing 401320, P.R. China
| | - Li Yang
- Department of Pathology, Banan Hospital of Chongqing Medical University, Chongqing 401320, P.R. China
| | - Ying Liu
- Department of Nuclear Medicine, Banan Hospital of Chongqing Medical University, Chongqing 401320, P.R. China
| |
Collapse
|
2
|
Ran L, Jiang L, Liu Y, Pang H. Evaluating the efficacy of 8Spheres microsphere embolization combined with iodine‑125 seed implantation in advanced refractory lung cancer: A retrospective study. Oncol Lett 2025; 29:285. [PMID: 40247985 PMCID: PMC12004036 DOI: 10.3892/ol.2025.15031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2025] [Accepted: 03/11/2025] [Indexed: 04/19/2025] Open
Abstract
Patients with advanced non-small cell lung cancer (NSCLC) have seen improvements in care; however, outcomes remain poor for certain individuals despite treatment with radiation, chemotherapy, targeted therapies and immunotherapy. The present study aimed to assess the safety and efficacy of combining 8Spheres microsphere embolization with iodine-125 seed implantation for treating advanced refractory NSCLC. The retrospective analysis included 45 patients with advanced refractory NSCLC. Using the surv_cutpoint function in R, the optimal maximum tumor diameter threshold was determined as 53 mm, dividing patients into two groups: ≤53 mm and >53 mm. The study evaluated the association between treatment regimen, tumor diameter, and progression-free survival (PFS) and overall survival (OS). The findings demonstrated that the experimental group achieved a significantly longer median PFS (12 vs. 10 months; P=0.006) and OS (19 vs. 12 months; P=0.032) compared with the control group. Both the treatment approach and tumor size were identified as independent factors influencing survival. The risk of death was 2.291-fold higher for patients on the control regimen than for those in the experimental group. Similarly, patients with a tumor diameter of >53 mm had a 2.723-fold higher risk of death than those with a tumor diameter of ≤53 mm. Adverse events were mild and resolved in both groups. In summary, the combination of 8Spheres microsphere embolization and iodine-125 seed implantation demonstrate promising clinical outcomes and it may be a viable treatment for advanced refractory NSCLC. Additionally, maximum tumor diameter was strongly associated with patient survival and therefore it may serve as a valuable prognostic indicator to guide treatment decisions.
Collapse
Affiliation(s)
- Linhao Ran
- Department of Nuclear Medicine, Banan People's Hospital, Chongqing Medical University, Chongqing 401320, P.R. China
- Department of Nuclear Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, P.R. China
| | - Li Jiang
- Department of Ultrasound, Banan People's Hospital, Chongqing Medical University, Chongqing 401320, P.R. China
| | - Ying Liu
- Department of Nuclear Medicine, Banan People's Hospital, Chongqing Medical University, Chongqing 401320, P.R. China
| | - Hua Pang
- Department of Nuclear Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, P.R. China
| |
Collapse
|
3
|
Tang G, Zhang Y, Meng W, Zhong S, Feng H, Yu G, Liu S, Li R. Iodine-125 seeds combined with anlotinib in the treatment of recurrent retroperitoneal liposarcoma after surgery: a case report. Front Oncol 2025; 15:1540868. [PMID: 40356749 PMCID: PMC12066600 DOI: 10.3389/fonc.2025.1540868] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2024] [Accepted: 04/01/2025] [Indexed: 05/15/2025] Open
Abstract
Retroperitoneal liposarcoma (RPLS) is a rare malignant mesenchymal tumor originating in the retroperitoneal space. It is characterized by a low incidence, poorly understood etiology and pathogenesis, and diverse imaging and pathological manifestations. The malignancy of RPLS varies significantly among cases. Currently, surgical resection remains the primary treatment for primary retroperitoneal liposarcoma; however, the disease is associated with a high and rapid recurrence rate, which severely impacts patient prognosis. This study presents a case of recurrent retroperitoneal liposarcoma treated with iodine-125 seed implantation following surgical intervention. Due to the large tumor size, high risk of postoperative recurrence, and the challenges of accurately targeting postoperative radiotherapy, surgical re-intervention was deemed unsuitable. Consequently, a comprehensive treatment plan involving iodine-125 seed implantation combined with anlotinib therapy was formulated. The patient achieved stable disease control over a 3-year follow-up period, demonstrating the potential efficacy of this combined therapeutic approach. This case highlights the antitumor potential of iodine-125 seed implantation combined with anlotinib in the management of retroperitoneal liposarcoma, particularly in cases where surgical options are limited.
Collapse
Affiliation(s)
- Gaoyan Tang
- Department of Oncology, Weifang People’s Hospital (The First Affiliated Hospital of Shandong Second Medical University), Weifang, China
| | - Yuping Zhang
- Center for Precision Pathological Diagnosis, Weifang People’s Hospital (The First Affiliated Hospital of Shandong Second Medical University), Weifang, China
| | - Wenjuan Meng
- Department of Oncology, Weifang People’s Hospital (The First Affiliated Hospital of Shandong Second Medical University), Weifang, China
| | - Shoubin Zhong
- Department of Oncology, Weifang People’s Hospital (The First Affiliated Hospital of Shandong Second Medical University), Weifang, China
| | - Hui Feng
- Department of Oncology, Weifang People’s Hospital (The First Affiliated Hospital of Shandong Second Medical University), Weifang, China
| | - Guohua Yu
- Department of Oncology, Weifang People’s Hospital (The First Affiliated Hospital of Shandong Second Medical University), Weifang, China
| | - Shuzhen Liu
- Department of Oncology, Weifang People’s Hospital (The First Affiliated Hospital of Shandong Second Medical University), Weifang, China
| | - Rui Li
- Department of Oncology, Weifang People’s Hospital (The First Affiliated Hospital of Shandong Second Medical University), Weifang, China
| |
Collapse
|
4
|
Guibin D, Xiaolan S, Wei Z, Xiaoli L, Liu D. Prediction of iodine-125 seed implantation efficacy in lung cancer using an enhanced CT-based nomogram model. PLoS One 2024; 19:e0313570. [PMID: 39546539 PMCID: PMC11567524 DOI: 10.1371/journal.pone.0313570] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2024] [Accepted: 10/26/2024] [Indexed: 11/17/2024] Open
Abstract
BACKGROUND Lung cancer, a leading cause of death, sees variable outcomes with iodine-125 seed implantation. Predictive tools are lacking, complicating clinical decisions. This study integrates radiomics and clinical features to develop a predictive model, advancing personalized treatment. OBJECTIVE To construct a nomogram model combining enhanced CT image features and general clinical characteristics to evaluate the efficacy of radioactive iodine-125 seed implantation in lung cancer treatment. METHODS Patients who underwent lung iodine-125 seed implantation at the Nuclear Medicine Department of Xiling Campus, Yichang Central People's Hospital from January 1, 2018, to January 31, 2024, were randomly divided into a training set (73 cases) and a test set (31 cases). Radiomic features were extracted from the enhanced CT images, and optimal clinical factors were analyzed to construct clinical, radiomics, and combined models. The best model was selected and validated for its role in assessing the efficacy of iodine-125 seed implantation in lung cancer patients. RESULTS Three clinical features and five significant radiomic features were successfully selected, and a combined nomogram model was constructed to evaluate the efficacy of iodine-125 seed implantation in lung cancer patients. The AUC values of the model in the training and test sets were 0.95 (95% CI: 0.91-0.99) and 0.83 (95% CI: 0.69-0.98), respectively. The calibration curve demonstrated good agreement between predicted and observed values, and the decision curve indicated that the combined model outperformed the clinical or radiomics model across the majority of threshold ranges. CONCLUSION A combined nomogram model was successfully developed to assess the efficacy of iodine-125 seed implantation in lung cancer patients, demonstrating good clinical predictive performance and high clinical value.
Collapse
Affiliation(s)
- Deng Guibin
- The First College of Clinical Medical Science, China Three Gorges University, Yichang Central People’s Hospital, Yichang, China
| | - Shen Xiaolan
- The First College of Clinical Medical Science, China Three Gorges University, Yichang Central People’s Hospital, Yichang, China
| | - Zhang Wei
- Yichang Hospital of Traditional Chinese Medicine, Yichang, China
| | - Lan Xiaoli
- Hubei Province Key Laboratory of Molecular Imaging, Wuhan, China
| | - Dehui Liu
- The First College of Clinical Medical Science, China Three Gorges University, Yichang Central People’s Hospital, Yichang, China
| |
Collapse
|
5
|
Ran L, Liu Y, Jiang L. Iodine‑125 seeds combined with carboplatin in the treatment of retroperitoneal metastatic seminoma: A case report and literature review. Oncol Lett 2024; 27:156. [PMID: 38426154 PMCID: PMC10902756 DOI: 10.3892/ol.2024.14289] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2023] [Accepted: 02/06/2024] [Indexed: 03/02/2024] Open
Abstract
Testicular seminoma is a relatively rare malignant tumor, with the most common site of recurrence and metastasis being the retroperitoneal lymph nodes. Since seminoma is highly sensitive to radiotherapy and chemotherapy, even if it metastasizes, its cure rate is still >95%. However, the long-term toxicity and side effects of radiotherapy and chemotherapy cannot be ignored. Iodine-125 seeds represent a low-energy radioactive source that kills tumor cells while protecting the surrounding normal tissues, and brachytherapy using iodine-125 seeds has been widely used for the treatment of various malignancies. In addition, carboplatin can be used as an alternative to cisplatin-based combination chemotherapy to reduce the incidence of pulmonary toxicity, neurological damage and renal toxicity. In the present study, a case in which iodine-125 seeds were implanted for the treatment of retroperitoneal metastatic seminoma is reported. The patient was diagnosed with postoperative recurrence of seminoma that metastasized to the retroperitoneal lymph nodes. Since the tumor was large and surrounded blood vessels, surgical intervention and external radiotherapy were not considered. Moreover, considering the potential long-term toxic side effects of standard chemotherapy, a treatment plan for the patient using iodine-125 seed implantation combined with carboplatin (AUC7) therapy was finally formulated. No disease recurrence or toxic reactions occurred during the 3-year follow-up after treatment. The present case therefore demonstrated the antitumor efficacy and reduced toxicity of iodine-125 seeds combined with carboplatin for treating seminoma.
Collapse
Affiliation(s)
- Linhao Ran
- Department of Radiology, People's Hospital of Chongqing Banan District, Chongqing 401320, P.R. China
| | - Ying Liu
- Department of Radiology, People's Hospital of Chongqing Banan District, Chongqing 401320, P.R. China
| | - Li Jiang
- Department of Ultrasound, People's Hospital of Chongqing Banan District, Chongqing 401320, P.R. China
| |
Collapse
|
6
|
Chen X, Chen X, Zhang C, Wang X, Yuan C, Yang H, Yang L. One case of iodine-125 therapy – A new minimally invasive treatment of intrahepatic cholangiocarcinoma. Open Life Sci 2022; 17:1309-1314. [PMID: 36249528 PMCID: PMC9518658 DOI: 10.1515/biol-2022-0473] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2021] [Revised: 06/27/2022] [Accepted: 07/07/2022] [Indexed: 11/15/2022] Open
Abstract
Abstract
Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver cancer associated with a poor prognosis. ICC accounts for about 10% of primary liver malignancies but with increasing incidence in recent years. Recently, some studies suggested that minimally interventional therapy can be used in the treatment of ICC. However, there are few references on interventional therapy for the clinical treatment of ICC. Herein we reported a case of a 48-year-old man who suffered from ICC. The patient was diagnosed with ICC by computerized tomography scan and pathological biopsy. The patient was completely cured by minimally interventional therapy with iodine-125 seed implantation. These results provide an important reference for the treatment option of ICC.
Collapse
Affiliation(s)
- Xinju Chen
- Department of Purchasing Center, The First Affiliated Hospital of Henan University of Chinese Medicine, No. 19, Renmin Road, Zhengzhou, Henan, 450000, P.R. China
| | - Xiaoqi Chen
- Department of Purchasing Center, The First Affiliated Hospital of Henan University of Chinese Medicine, No. 19, Renmin Road, Zhengzhou, Henan, 450000, P.R. China
| | - Chuanlei Zhang
- Department of Purchasing Center, The First Affiliated Hospital of Henan University of Chinese Medicine, No. 19, Renmin Road, Zhengzhou, Henan, 450000, P.R. China
| | - Xinting Wang
- Department of Purchasing Center, The First Affiliated Hospital of Henan University of Chinese Medicine, No. 19, Renmin Road, Zhengzhou, Henan, 450000, P.R. China
| | - Changwei Yuan
- Department of Purchasing Center, The First Affiliated Hospital of Henan University of Chinese Medicine, No. 19, Renmin Road, Zhengzhou, Henan, 450000, P.R. China
| | - He Yang
- Department of Purchasing Center, The First Affiliated Hospital of Henan University of Chinese Medicine, No. 19, Renmin Road, Zhengzhou, Henan, 450000, P.R. China
| | - Lixia Yang
- Department of Purchasing Center, The First Affiliated Hospital of Henan University of Chinese Medicine, No. 19, Renmin Road, Zhengzhou, Henan, 450000, P.R. China
| |
Collapse
|
7
|
Sofuni A, Asai Y, Mukai S, Yamamoto K, Itoi T. High-intensity focused ultrasound therapy for pancreatic cancer. J Med Ultrason (2001) 2022:10.1007/s10396-022-01208-4. [PMID: 35551555 DOI: 10.1007/s10396-022-01208-4] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2022] [Accepted: 03/01/2022] [Indexed: 11/28/2022]
Abstract
Pancreatic cancer (PC) has one of the poorest prognoses among solid cancers, and its incidence has increased recently. Satisfactory outcomes are not achieved with current therapies; thus, novel treatments are urgently needed. High-intensity focused ultrasound (HIFU) is a novel therapy for ablating tissue from the outside of the body by focusing ultrasonic waves from multiple sources on the tumor. In this therapy, only the focal area is heated to 80-100 ºC, which causes coagulative necrosis of the tissue, with hardly any impact on the tissue outside the focal area. Although HIFU is a minimally invasive treatment and is expected to be useful, it is not yet generally known. Here, we discuss the usefulness of HIFU treatment for un-resectable advanced PC using the results of previous research, meta-analyses, and systematic reviews on its efficacy and safety. HIFU therapy for un-resectable PC is useful for its anti-tumor effect and pain relief, and is expected to prolong survival time and improve quality of life. Although HIFU for PC has several limitations and further study is needed, this technique can be safely performed on un-resectable advanced PC. In future, HIFU could be utilized as a minimally invasive treatment strategy for PC patients with a poor prognosis.
Collapse
Affiliation(s)
- Atsushi Sofuni
- Department of Gastroenterology and Hepatology, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan.
| | - Yasutsugu Asai
- Department of Gastroenterology and Hepatology, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan
| | - Shuntaro Mukai
- Department of Gastroenterology and Hepatology, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan
| | - Kenjiro Yamamoto
- Department of Gastroenterology and Hepatology, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan
| | - Takao Itoi
- Department of Gastroenterology and Hepatology, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan
| |
Collapse
|
8
|
Li CG, Zhou ZP, Jia YZ, Tan XL, Song YY. Radioactive 125I seed implantation for pancreatic cancer with unexpected liver metastasis: A preliminary experience with 26 patients. World J Clin Cases 2021; 9:792-800. [PMID: 33585625 PMCID: PMC7852643 DOI: 10.12998/wjcc.v9.i4.792] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/16/2020] [Revised: 12/03/2020] [Accepted: 12/10/2020] [Indexed: 02/06/2023] Open
Abstract
BACKGROUND Preoperative diagnosis rate of pancreatic cancer has increased year by year. The prognosis of pancreatic cancer patients with unexpected liver metastasis found by intraoperative exploration is very poor, and there is no effective and unified treatment strategy.
AIM To evaluate the therapeutic effect of radioactive 125I seed implantation for pancreatic cancer patients with unexpected liver metastasis.
METHODS The demographics and perioperative outcomes of patients who underwent 125I seed implantation to treat pancreatic cancer with unexpected liver metastasis between January 1, 2017 and June 1, 2019 were retrospectively analyzed. During the operation, 125I seeds were implanted into the pancreatic tumor under the guidance of intraoperative ultrasound, with a spacing of 1.5 cm and a row spacing of 1.5 cm. For patients with obstructive jaundice and digestive tract obstruction, choledochojejunostomy and gastroenterostomy were performed simultaneously. After operation, the patients were divided into a non-chemotherapy group and a chemotherapy group that received gemcitabine combined with albumin-bound paclitaxel treatment.
RESULTS Preoperative imaging evaluation of all patients in this study showed that the tumor was resectable without liver metastasis. There were 26 patients in this study, including 18 males and 8 females, aged 60.5 ± 9.7 years. The most common tumor site was the pancreatic head (17, 65.4%), followed by the pancreatic neck and body (6, 23.2%) and pancreatic tail (3, 11.4%). Fourteen patients (53.8%) underwent palliative surgery and postoperative pain relief occurred in 22 patients (84.6%). The estimated blood loss in operation was 148.3 ± 282.1 mL and one patient received blood transfusion. The postoperative hospital stay was 7.6 ± 2.8 d. One patient had biliary fistula, one had pancreatic fistula, and all recovered after conservative treatment. After operation, 7 patients received chemotherapy and 19 did not. The 1-year survival rate was significantly higher in patients who received chemotherapy than in those who did not (68.6% vs 15.8%, P = 0.012). The mean overall survival of patients in the chemotherapy group and non-chemotherapy group was 16.3 mo and 10 mo, respectively (χ2 = 7.083, P = 0.008).
CONCLUSION Radioactive 125I seed implantation combined with postoperative chemotherapy can prolong the survival time and relieve pain of pancreatic cancer patients with unexpected liver metastasis.
Collapse
Affiliation(s)
- Cheng-Gang Li
- Second Department of Hepatobiliary Surgery, Chinese PLA General Hospital, Beijing 100853, China
| | - Zhi-Peng Zhou
- Second Department of Hepatobiliary Surgery, Chinese PLA General Hospital, Beijing 100853, China
| | - Yu-Ze Jia
- Second Department of Hepatobiliary Surgery, Chinese PLA General Hospital, Beijing 100853, China
| | - Xiang-Long Tan
- Second Department of Hepatobiliary Surgery, Chinese PLA General Hospital, Beijing 100853, China
| | - Yu-Yao Song
- Second Department of Hepatobiliary Surgery, Chinese PLA General Hospital, Beijing 100853, China
| |
Collapse
|
9
|
Qiu B, Jiang P, Ji Z, Huo X, Sun H, Wang J. Brachytherapy for lung cancer. Brachytherapy 2020; 20:454-466. [PMID: 33358847 DOI: 10.1016/j.brachy.2020.11.009] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2020] [Revised: 11/07/2020] [Accepted: 11/17/2020] [Indexed: 12/24/2022]
Abstract
Brachytherapy (BT) is a minimally invasive anticancer radiotherapeutic modality where the tumor is directly irradiated via a radioactive source that is precisely implanted in or adjacent to the tumor. BT for lung cancer may be conducted in the form of endobronchial BT and radioactive seed implantation (RSI-BT), mainly for nonsmall cell lung cancer (NSCLC). For patients with early-stage lung cancer who are not suitable for surgery or external beam radiotherapy (EBRT), BT may be used as an alternative treatment, and curative results could be achieved in certain patients with cancer confined to the trachea lumen. For patients with locally advanced/metastatic lung cancer, BT could be selectively applied alone or as a boost to EBRT, which could improve the local tumor control and patient's survival. In addition, BT is also useful as a salvage treatment in select patients with locally recurrent/residual lung cancer that failed other treatments (e.g., surgery, chemotherapy, and EBRT). However, clinical outcomes are mainly obtained from retrospective studies. Prospective studies are limited and needed. In recent years, the introduction of modern image guidance, novel radioactive seeds, BT treatment planning systems (BT-TPS), after-loading technique, and three-dimensional printing template (3D-PT) assistance, among others, have potentially improved the clinical outcomes of BT. However, a comprehensive review of BT with newly published literature was lacking. This review is to discuss BT for NSCLC based on recent literature published in PubMed.
Collapse
Affiliation(s)
- Bin Qiu
- Department of Radiation Oncology, Peking University Third Hospital, Beijing, China; Department of Radiation Oncology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Ping Jiang
- Department of Radiation Oncology, Peking University Third Hospital, Beijing, China
| | - Zhe Ji
- Department of Radiation Oncology, Peking University Third Hospital, Beijing, China
| | - Xiaodong Huo
- Department of Thoracic Surgery, Tianjin Medical University 2nd Hospital, Department of Oncology, Tianjin Medical University 2nd Hospital, Tianjin, China
| | - Haitao Sun
- Department of Radiation Oncology, Peking University Third Hospital, Beijing, China
| | - Junjie Wang
- Department of Radiation Oncology, Peking University Third Hospital, Beijing, China.
| |
Collapse
|
10
|
Xu F, Yang J, Xu B, Li Z, Li X, Wu X, Liu H. Clinical Research on Systemic Chemotherapy Combined With Bronchoscopic Seed Implantation in the Treatment of Advanced Lung Cancer. Technol Cancer Res Treat 2020; 19:1533033820971600. [PMID: 33280522 PMCID: PMC7724264 DOI: 10.1177/1533033820971600] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
Objective: This study aims to explore the clinical value of systemic chemotherapy
combined with bronchoscopic seed implantation in advanced lung cancer
treatment. Methods: The study enrolled 253 patients with advanced lung cancer in Cangzhou
People’s Hospital from March 2018 to March 2020, and they were divided into
test group and control group. Test group was given systemic chemotherapy
combined with bronchoscopic seed implantation, while control group was given
systemic chemotherapy. The objective response rate of tumor (ORR), disease
control rate (DCR), serum tumor marker level, survival time and adverse
reactions of 2 groups were compared. Results: After treatment, the levels of serum tumor markers including
carcino-embryonic antigen, neuro-specific enolase, cytokeratin-19 and
pro-gastrin-releasing peptide were markedly decreased in test group compared
with those in control group (P < 0.05). Therein, the
serum tumor marker level of non-small cell lung cancer (NSCLC) patients was
significant decreased compared with that of small cell lung cancer (SCLC)
patients in test group. Meanwhile, in test group, the serum tumor marker
level of lung adenocarcinoma (LUAD) patients was significant decreased
compared with that of lung squamous cell carcinoma (LUSC, P
< 0.05). The ORR and DCR in test group were superior to those in control
group (63.4%, 92.5% vs 38.7%, 72.3%, P
< 0.05), while those were much higher in patients with NSCLC and LUAD
relative to those in patients with SCLC and LUSC, respectively
(P < 0.05). Furthermore, the progression-free
survival (PFS) and overall survival (OS) in test group were significantly
greater than those in control group. In test group, the PFS and OS of
patients with NSCLC and LUAD were higher than those of patients with SCLC
and LUSC. Conclusion: The efficacy of systemic chemotherapy combined with bronchoscopic seed
implantation was superior to that of systemic chemotherapy, which is worthy
of promoting in clinical practice.
Collapse
Affiliation(s)
- Feng Xu
- Department of Pulmonary and Critical Care Medicine, Cangzhou People's Hospital, Cangzhou, China
| | - Jian Yang
- Department of Radiation Oncology, Cangzhou People's Hospital, Cangzhou, China
| | | | - Zhenzhen Li
- Department of Pulmonary and Critical Care Medicine, Cangzhou People's Hospital, Cangzhou, China
| | - Xuanmei Li
- Department of Pulmonary and Critical Care Medicine, Cangzhou People's Hospital, Cangzhou, China
| | - Xiaotang Wu
- Shanghai Engineering Research Center of Pharmaceutical Translation, Shanghai, China
| | - Haiyan Liu
- Department of Pulmonary and Critical Care Medicine, Cangzhou People's Hospital, Cangzhou, China
| |
Collapse
|
11
|
Li CG, Zhou ZP, Jia YZ, Tan XL, Song YY. Radioactive 125I seed implantation for locally advanced pancreatic cancer: A retrospective analysis of 50 cases. World J Clin Cases 2020; 8:3743-3750. [PMID: 32953850 PMCID: PMC7479562 DOI: 10.12998/wjcc.v8.i17.3743] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/14/2020] [Revised: 05/25/2020] [Accepted: 08/12/2020] [Indexed: 02/05/2023] Open
Abstract
BACKGROUND Pancreatic cancer is one of the common malignant tumors of the digestive system, and radical resection is the first choice of treatment for pancreatic cancer. If patients with locally advanced pancreatic cancer cannot be treated in time and effectively, their disease often develops rapidly and their survival period is very short.
AIM To evaluate the therapeutic effect of 125I seed implantation in patients with locally advanced pancreatic cancer.
METHODS The demographics and perioperative outcomes of a consecutive series of patients who underwent 125I seed implantation to treat locally advanced pancreatic cancer between January 1, 2017 and June 30, 2019 were retrospectively analyzed. According to the results of preoperative computed tomography or magnetic resonance imaging, the treatment planning system was used to determine the area and number of 125I seeds implanted. During the operation, 125I seeds were implanted into the tumor under the guidance of intraoperative ultrasound, with a spacing of 1.5 cm and a row spacing of 1.5 cm. For patients with obstructive jaundice and digestive tract obstruction, choledochojejunostomy and gastroenterostomy were performed simultaneously. After operation, the patients were divided into a non-chemotherapy group and a chemotherapy group that received gemcitabine combined with albumin-bound paclitaxel treatment.
RESULTS Among the 50 patients, there were 29 males and 21 females, with a mean age of 56.9 ± 9.8 years. The main reason for the failure of radical resection was superior mesenteric artery invasion (37, 74%), followed by superior mesenteric vein invasion (33, 66%). Twenty-one (62%) patients underwent palliative surgery and postoperative pain relief occurred in 40 (80%) patients. The estimated blood loss in operation was 107.4 ± 115.3 mL and none of the patient received blood transfusion. The postoperative hospital stay was 7.5 ± 4.2 d; one patient had biliary fistula and three had pancreatic fistula, all of whom recovered after conservative treatment. After operation, 26 patients received chemotherapy and 24 did not. The 1-year survival rate was significantly higher in patients who received chemotherapy than in those who did not (60.7% vs 35.9%, P = 0.034). The mean overall survival of patients of the chemotherapy group and non-chemotherapy group was 14 and 11 mo, respectively (χ2 = 3.970, P = 0.046).
CONCLUSION Radioactive 125I seed implantation combined with postoperative chemotherapy can prolong the survival time, relieve pain, and improve the quality of life of patients with locally advanced pancreatic cancer.
Collapse
Affiliation(s)
- Cheng-Gang Li
- Second Department of Hepatobiliary Surgery, Chinese PLA General Hospital, Beijing 100853, China
| | - Zhi-Peng Zhou
- Second Department of Hepatobiliary Surgery, Chinese PLA General Hospital, Beijing 100853, China
| | - Yu-Ze Jia
- Second Department of Hepatobiliary Surgery, Chinese PLA General Hospital, Beijing 100853, China
| | - Xiang-Long Tan
- Second Department of Hepatobiliary Surgery, Chinese PLA General Hospital, Beijing 100853, China
| | - Yu-Yao Song
- Second Department of Hepatobiliary Surgery, Chinese PLA General Hospital, Beijing 100853, China
| |
Collapse
|